CoChat

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes, may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease in maximum concentration (Cmax). This study evaluated the drug interaction potential of exenatide when administered adjunctively with oral contraceptives, given their potential concomitant use. METHODS: This trial evaluated the effect of exenatide co-administration on single- and multiple-dose pharmacokinetics of a combination oral contraceptive (ethinyl estradiol [EE] 30 μg, levonorgestrel [LV] 150 μg [Microgynon 30®]). Thirty-two healthy female subjects participated in an open-label, randomised, crossover trial with 3 treatment periods (oral contraceptive alone, 1 hour before exenatide, 30 minutes after exenatide). Subjects received a single dose of oral contraceptive on Day 8 of each period and QD doses on Days 10 through 28. During treatment periods of concomitant usage, exenatide was administered subcutaneously prior to morning and evening meals at 5 μg BID from Days 1 through 4 and at 10 μg BID from Days 5 through 22. Single- (Day 8) and multiple-dose (Day 22) pharmacokinetic profiles were assessed for each treatment period. RESULTS: Exenatide did not alter the bioavailability nor decrease daily trough concentrations for either oral contraceptive component. No substantive changes in oral contraceptive pharmacokinetics occurred when oral contraceptive was administered 1 hour before exenatide. Single-dose oral contraceptive administration 30 minutes after exenatide resulted in mean (90% CI) Cmax reductions of 46% (42-51%) and 41% (35-47%) for EE and LV, respectively. Repeated daily oral contraceptive administration 30 minutes after exenatide resulted in Cmax reductions of 45% (40-50%) and 27% (21-33%) for EE and LV, respectively. Peak oral contraceptive concentrations were delayed approximately 3 to 4 hours. Mild-to-moderate nausea and vomiting were the most common adverse events observed during the trial. CONCLUSIONS: The observed reduction in Cmax is likely of limited importance given the unaltered oral contraceptive bioavailability and trough concentrations; however, for oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before exenatide injection. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00254800.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1472-6904-12-8

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean single-dose plasma concentration-time profiles for ethinyl estradiol.
Figure 1 Mean single-dose plasma concentration-time profiles for ethinyl estradiol.CC BY · PubMed Central
Figure 2 Mean single-dose plasma concentration-time profiles for levonorgestrel.
Figure 2 Mean single-dose plasma concentration-time profiles for levonorgestrel.CC BY · PubMed Central
Figure 3 Mean steady-state plasma concentration-time profiles for ethinyl estradiol.
Figure 3 Mean steady-state plasma concentration-time profiles for ethinyl estradiol.CC BY · PubMed Central
Figure 4 Mean steady-state plasma concentration-time profiles for levonorgestrel.
Figure 4 Mean steady-state plasma concentration-time profiles for levonorgestrel.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Reddy S, Park S, Fineman M, Jay L, Carter M, Reynolds L, Sanburn N, Kothare PA: Clinical pharmacokinetics of exenatide in patients with type 2 diabetes [abstract]. AAPS J. 2005, 7: M1285-

Cited by

See all 37

Metadata

Authors
Kothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H.
Affiliations
  • Eli Lilly (United States) (US)
  • Eli Lilly (United Kingdom) (GB)
Corresponding author
Kothare, Prajakti A
Venue
BMC Clinical Pharmacology
Published
2012-03-19
Volume
12
Issue
1
Pages
8-8
ISSN
1472-6904 (ISSN-L)
OpenAlex
W2059979713
Cited by
35
References
24
Citations by year
2026: 5 · 2025: 6 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 1 · 2014: 6 · 2013: 1 · 2012: 2
FWCI
3.62
Type
journal article
Language
en
Open access
Locations
  • BMC Clinical Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
exenatide, combined oral contraceptives, drug interactions, pharmacokinetics, ethinyl estradiol, levonorgestrel, gastric emptying, bioavailability, type 2 diabetes, nausea and vomiting, women of reproductive age, timing of drug administration
MeSH terms
Exenatide, Adult, Contraceptives, Oral, Combined, Drug Interactions, Ethinyl Estradiol, Female, Humans, Hypoglycemic Agents, Peptides, Venoms, Levonorgestrel, Cross-Over Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. https://app.cochat.ai/papers/10.1186/1472-6904-12-8
The paper
Kothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H. (2012). Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clinical Pharmacology. https://doi.org/10.1186/1472-6904-12-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.